Physician profile
Peter Li
NPI 1942709647
$2,877.68
in general payments reported to CMS, 2019-2025
36 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $409 · 2021: $24.88 · 2022: $222 · 2023: $728 · 2024: $904 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $360.68 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $250.42 | 2023-2024 | Xpovio |
| Amgen INC. | $186.55 | 2020-2023 | Lumakras |
| Gilead Sciences, INC. | $167.13 | 2024-2025 | Trodelvy |
| Sobi, INC | $155.75 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $136.16 | 2023 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.56 | 2020 | |
| Genmab U.S., INC. | $132.50 | 2024 | Epkinly |
| Tempus Ai, INC | $121.42 | 2024 | |
| Allergan, INC. | $120.00 | 2019 | |
| Abbvie INC. | $113.89 | 2024-2025 | |
| Cardiovascular Systems INC. | $106.76 | 2020 | |
| Tactile Systems Technology INC | $93.77 | 2025 | Nimbl, Flexitouch Plus |
| Incyte Corporation | $80.93 | 2022-2023 | Jakafi |
| Mirati Therapeutics, INC. | $76.26 | 2023-2024 | Krazati |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $61.55 | 2023 | Epkinly |
| Astrazeneca Pharmaceuticals Lp | $57.22 | 2022-2024 | |
| Celgene Corporation | $46.08 | 2022-2023 | Pomalyst |
| Recordati_rare_diseases_inc. | $45.60 | 2023 | Sylvant |
| Ipsen Biopharmaceuticals, INC | $43.16 | 2022 | |
| Aveo Pharmaceuticals, INC. | $42.00 | 2023-2024 | Fotivda |
| Alexion Pharmaceuticals, INC. | $39.93 | 2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $28.00 | 2023 | Givlaari |
| Tersera Therapeutics LLC | $26.19 | 2023 | Xermelo |
| Exelixis INC. | $24.88 | 2021 | |
| Glaxosmithkline, LLC. | $24.86 | 2022 | |
| Coherus Oncology, INC. | $23.28 | 2024 | |
| Immunogen, INC. | $23.27 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Rezlidhia, Tavalisse |
| Sanofi-Aventis U.S. LLC | $22.56 | 2022 | |
| Morphosys, US INC. | $22.48 | 2024 | Monjuvi |
| Adc Therapeutics America, INC. | $21.75 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Cti Biopharma Corp. | $18.59 | 2023 | Vonjo |
| Medtronic Vascular, INC. | $15.00 | 2020 | |
| Merck Sharp & Dohme LLC | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.